Kinarus has reported that its preclinical data on lead candidate KIN001 have shown strong antiviral efficacy against SARS-CoV-2 Omicron subvariants BA.2 and BA.5, which account for about a quarter of US COVID-19 infections. This builds on previously reported in vitro data, indicative of robust antiviral efficacy of equal potency against the original SARS-CoV-2 strain and other variants of concern, including Delta. We view this development as continued validation of KIN001's mechanism of action involving antiviral, anti-inflammatory and anti-fibrotic activity, as well as its 'variant-agnostic' level of activity against SARS-CoV-2. We highlight that other SARS-CoV-2 variants are emerging, including the Omicron BQ subvariants, and KIN001's effectiveness to date against multiple variants suggests it may also maintain potency against BQ and other future (sub)variants as well.Den vollständigen Artikel lesen ...
© 2022 Edison Investment Research
